Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Gastroenterology and hepatology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Dyspepsia and epigastric pain

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Epigastric pain with haemodynamic instability, haematemesis or melaena, rigid peritonism, sudden severe pain, acute coronary features, persistent vomiting with dehydration, jaundice and sepsis, or severe pain with organ dysfunction needs urgent hospital assessment. Do not place a shocked or bleeding patient into a routine dyspepsia test-and-treat pathway.

Overview

Distinguish uncomplicated dyspepsia from cardiac, biliary, pancreatic, ulcer and malignant disease, use Helicobacter pylori testing correctly, and sequence treatment, endoscopy and review safely.

Epigastric symptoms require precise language. Epigastric pain syndrome describes pain or burning centred above the umbilicus; postprandial distress features early satiation and uncomfortable fullness. Heartburn rises retrosternally, while biliary pain generally builds to a sustained severe epigastric or right upper-quadrant episode and is not simply meal-responsive indigestion. Pancreatitis produces persistent pain, often radiating to the back, with vomiting and systemic illness. Peptic ulcer disease may cause localised dyspepsia or present only when it bleeds or perforates. No timing rule reliably distinguishes benign from serious disease, so physiology and warning features come first.

Assessment should identify cancer risk and reversible causes. Record age, symptom onset and progression, dysphagia, odynophagia, weight trajectory, vomiting, bleeding, anaemia, family history and previous ulcer or gastric surgery. Ask about NSAID and aspirin exposure, including over-the-counter products, tobacco and alcohol. Examination looks for pallor, cachexia, nodes, oral signs, jaundice, abdominal mass, organomegaly and tenderness; a normal examination is common in both functional dyspepsia and early structural disease. Apply the current NICE NG12 recommendations rather than memorising an isolated age threshold because symptom combinations and pathway wording can change.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Gastroenterology and hepatologyOriginal SBA

Preparing H pylori testing

A stable adult with uncomplicated dyspepsia is taking a proton-pump inhibitor and is booked for a urea breath test for Helicobacter pylori. Which instruction best improves test validity?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Gastroenterology and hepatology topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG184 dyspepsia and refluxH pylori testing, PPI trials, eradication, endoscopy and long-term review.
  • NICE NG12 suspected upper gastrointestinal cancerCurrent symptom combinations and referral routes for oesophageal, gastric and pancreatic cancer.
  • BSG functional dyspepsia guidelinePositive diagnosis and layered management of functional dyspepsia.
  • NICE QS96 dyspepsia quality standardQuality statements for testing, urgent endoscopy and acid-suppression review.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

In a stable person without an urgent endoscopy indication, choose between non-invasive H pylori test-and-treat and empirical PPI treatment according to NICE and local practice. Urea breath testing or monoclonal stool antigen testing requires removal of PPI suppression for two weeks; recent antibiotics can also cause false-negative results. If symptoms persist after eradication or adequate acid suppression, confirm what was actually taken, revisit warning features and consider endoscopy or alternative imaging. A normal endoscopy with a compatible phenotype supports functional dyspepsia, which is managed through explanation, regular smaller meals, avoidance of individual triggers rather than blanket restriction, and selected pharmacological or psychological treatment.

Key points

  • Dyspepsia includes epigastric pain or burning, postprandial fullness and early satiation; retrosternal heartburn and regurgitation can overlap but point more towards reflux.
  • Ask about exertion, breathlessness, diaphoresis and cardiovascular risk because inferior cardiac ischaemia can present as epigastric discomfort, especially in older adults and people with diabetes.
  • Dysphagia, weight loss, anaemia, haematemesis, persistent vomiting, an upper abdominal mass and age-linked new symptoms trigger the current endoscopy or suspected-cancer pathway.
  • Review NSAIDs, aspirin, corticosteroid combinations, bisphosphonates, iron, potassium and medicines affecting gastric emptying before assuming primary acid disease.
  • For non-invasive Helicobacter pylori testing, arrange a two-week proton-pump inhibitor washout and avoid testing too soon after antibiotics, following the selected assay and local laboratory instructions.
  • NICE supports H pylori test-and-treat and a time-limited full-dose PPI trial for uninvestigated dyspepsia without alarm features; sequence and local access should be explicit.
  • Do not use symptom response to a PPI as proof of benign disease. Reassess adherence, indication, warning features and alternative biliary, pancreatic or cardiac causes when symptoms persist.

Aetiology

01

Acid and mucosal disease

Helicobacter pylori, peptic ulcer, reflux and NSAID-related injury commonly cause upper abdominal burning or pain, sometimes with bleeding or anaemia.

02

Functional dyspepsia

Disordered gastric accommodation, visceral sensitivity and gut-brain signalling can produce early satiation, postprandial fullness or epigastric pain without explanatory structural disease.

03

Non-gastric pathology

Biliary, pancreatic, cardiac, vascular and malignant disease may present as epigastric discomfort and should be separated using timing, alarms and targeted tests.

Pathophysiology

  1. 1
    Mucosal irritation

    Acid, infection or medicines disrupt gastric or duodenal defences, exposing sensory pathways and sometimes causing ulceration.

  2. 2
    Impaired accommodation and sensitivity

    Abnormal fundic relaxation, gastric emptying or heightened visceral afferent responses make normal meals feel painfully full or cause early satiation.

  3. 3
    Referred or obstructive pain

    Cardiac ischaemia, pancreatic inflammation, biliary pressure or gastric outlet obstruction activates overlapping visceral segments, making symptom location alone unreliable.

Clinical features and red flags

Uncomplicated dyspepsia phenotype

Intermittent epigastric pain, burning, early satiation or postprandial fullness without bleeding, anaemia, weight loss, progressive vomiting, dysphagia or mass supports initial primary-care management after relevant medicine and cardiac review.

Upper gastrointestinal cancer warningRed flag

Progressive dysphagia, unexplained weight loss with upper abdominal symptoms, iron-deficiency anaemia, persistent vomiting, haematemesis or an epigastric mass moves assessment to the current urgent endoscopy or suspected-cancer pathway.

Peptic ulcer complicationRed flag

Melaena, haematemesis, syncope or anaemia suggests bleeding; sudden severe generalised pain with rigidity suggests perforation. NSAIDs, aspirin, H pylori and previous ulcer disease raise probability.

Cardiac epigastric presentationRed flag

Pressure, exertional association, breathlessness, sweating, radiation or cardiovascular risk should prompt ECG and acute coronary assessment. Reproducible meal association and antacid response cannot safely exclude myocardial ischaemia.

Functional dyspepsia

Chronic epigastric pain or meal-related fullness with no explanatory structural disease and no new warning feature supports a gut-brain interaction disorder. Symptoms remain real and may coexist with reflux or IBS.

Investigations

  1. 01
    ECG and cardiac biomarkersFirst step
    Why
    Exclude acute coronary syndrome when epigastric discomfort has exertional, autonomic or cardiovascular-risk features.
    Interpretation and limitations
    Follow the acute chest-pain pathway; one normal ECG does not exclude evolving ischaemia. Do not postpone cardiac assessment while trialling antacid treatment.
  2. 02
    Full blood count and ferritin
    Why
    Identify iron-deficiency anaemia or blood loss that changes endoscopy urgency and cancer probability.
    Interpretation and limitations
    Iron deficiency needs a gastrointestinal and other cause assessment appropriate to age and context. A normal count does not exclude ulcer or early cancer when warning symptoms persist.
  3. 03
    Urea breath test or stool antigen
    Why
    Detect active H pylori infection non-invasively and select eradication treatment in uncomplicated dyspepsia.
    Interpretation and limitations
    Stop PPI for two weeks and respect the assay interval after antibiotics. Serology may remain positive after eradication and is not generally suitable for confirming cure; local testing pathways govern.
  4. 04
    Liver profile and lipase
    Why
    Assess biliary obstruction, hepatitis or pancreatitis when pain quality, jaundice or systemic illness makes these plausible.
    Interpretation and limitations
    A cholestatic pattern supports biliary imaging, while appropriately elevated lipase with compatible pain supports pancreatitis. Normal tests

Differential diagnosis

01

Acute coronary syndrome

Exertional pressure, breathlessness, sweating, cardiovascular risk or ECG change requires cardiac assessment, especially in older adults and people with diabetes.

02

Ulcer or upper-GI cancer

Bleeding, iron-deficiency anaemia, weight loss, dysphagia, persistent vomiting or a mass requires prompt endoscopy rather than prolonged empirical treatment.

03

Biliary or pancreatic disease

Right-upper-quadrant attacks, jaundice, back radiation, persistent severe pain or abnormal liver and pancreatic tests support hepatopancreatobiliary imaging.

Additional chapter-specific clues

Biliary or pancreatic alternative

Sustained right upper-quadrant or epigastric attacks, jaundice or fever point to biliary disease, while persistent back-radiating pain with vomiting and systemic change supports pancreatitis. These require targeted blood tests and imaging, not routine dyspepsia treatment alone.

Management

01TriageSeparate emergency and alarm diseaseFirst stepA patient presents with new or worsening epigastric pain or dyspepsia.+
  1. 1Check haemodynamics and look for bleeding, peritonism, cardiac ischaemia, jaundice with sepsis and severe dehydration, sending unstable patients to acute care.
  2. 2Elicit dysphagia, weight loss, anaemia, persistent vomiting, mass, family history and age-linked onset, then apply the current NG12 and endoscopy pathway.
  3. 3Review ulcerogenic and motility-altering medicines and identify biliary, pancreatic and cardiac features before assigning uncomplicated dyspepsia.
  4. 4Document the chosen pathway, expected response and named trigger for earlier reassessment.
02Initial treatmentTest or suppress acid deliberatelyStable uninvestigated dyspepsia has no urgent endoscopy indication.+
  1. 1

Complications

01

Bleeding, perforation or obstruction

Unrecognised ulcer or tumour may haemorrhage, perforate or block gastric emptying, converting a common symptom into an acute surgical or resuscitation emergency.

02

Weight loss and nutritional decline

Early satiety, pain or vomiting can reduce intake and cause dehydration, sarcopenia and deficiencies even when the disorder is non-malignant.

03

Delayed serious diagnosis

Repeated acid suppression without reviewing alarm features can postpone cancer, cardiac, biliary or pancreatic diagnosis and create avoidable harm.

Monitoring and follow-up

  • Record haemoglobin and any overt bleeding, weight trajectory, vomiting, swallowing difficulty and symptom progression at each review rather than monitoring pain alone.
  • Track every H pylori result to treatment or documented negative action, and confirm that pre-test PPI and antibiotic washout made the result interpretable.
  • Review PPI benefit after the planned course, attempt step-down where safe and record the indication when continuing long term.
  • Ensure urgent endoscopy referrals and histology have a named reviewer, with safety-netting if access is delayed or symptoms worsen.
  • For functional dyspepsia, follow early satiation, nutritional intake, weight and functional impact, escalating dietetic support if restriction develops.

Special situations

Dyspepsia is a symptom family

Epigastric burning, early satiation and postprandial fullness reflect different mechanisms. Naming the dominant feature makes treatment and reconsideration more precise than calling every upper abdominal sensation reflux.

PPI response lacks specificity

Acid suppression can improve ulcer, reflux and functional symptoms through several pathways. Clinical improvement therefore supports continued management but cannot prove benignity or exclude cancer when warning features exist.

Test preparation changes truth

PPI and recent antibiotic exposure suppress H pylori and create false-negative breath or stool tests. Recording washout is part of interpretation, not merely an administrative instruction.

Eradication and cure differ

Prescribing an eradication pack does not establish microbiological success. Adherence, resistance and indication determine whether a correctly timed non-invasive confirmation test is required.

Meal symptoms can starve

Early satiation may lead to progressive food avoidance even without weight loss at presentation. Small regular meals and early dietetic review protect nutrition while organic and functional causes are addressed.

Common pitfalls

  1. 01

    Treating exertional epigastric pressure as indigestion without an ECG or acute coronary assessment.

  2. 02

    Performing an H pylori breath or stool test while the patient continues a proton-pump inhibitor.

  3. 03

    Using a successful PPI trial to overrule progressive dysphagia, anaemia or weight loss.

  4. 04

    Repeating eradication antibiotics without checking adherence, prior exposure and the local resistance-led rescue pathway.

  5. 05

    Calling sustained right upper-quadrant attacks functional dyspepsia without biliary investigation.

  6. 06

    Renewing long-term acid suppression without recording indication, benefit or a step-down review.

Functional dyspepsia is a positive disorder of gut-brain interaction after appropriate assessment; explain meal-related sensitivity and offer layered dietary, acid-suppressing and neuromodulatory options.
  • After control, step down acid suppression to the lowest effective strategy and review long-term indication rather than renewing treatment indefinitely without ownership.
    • do not
    explain progressive dysphagia, bleeding or weight loss.
  • 05
    Upper gastrointestinal endoscopy
    Why
    Identify cancer, ulcer, oesophagitis, stricture and other mucosal disease when warning features or persistent symptoms justify direct visualisation.
    Interpretation and limitations
    Biopsy strategy and rapid-access timing follow indication and local standards. A normal examination supports but does not by itself define functional dyspepsia; review whether biliary, pancreatic or motility questions remain.
  • 06
    Abdominal ultrasound or cross-sectional imaging
    Why
    Investigate gallstones, biliary dilatation, pancreatic or other structural disease when the phenotype is not luminal dyspepsia.
    Interpretation and limitations
    Ultrasound is first-line for gallstone questions, while CT or MR techniques answer pancreatic and ductal questions. Do not substitute endoscopy for a strong biliary hypothesis or vice versa.
    • Choose H pylori test-and-treat or a four-week full-dose PPI trial according to NICE and local sequence, explaining that each is a time-limited diagnostic-management step.
  • 2If testing, arrange appropriate PPI and antibiotic washout, use a validated breath or stool assay and establish who will act on the result.
  • 3Treat confirmed infection using the current local eradication regimen, then review symptom response and whether post-treatment confirmation is indicated.
  • 4For PPI response, step down after the initial course and reassess rather than allowing indefinite repeat prescribing without diagnosis or review.
    • 03Persistent symptomsCheck premise before escalationEscalationSymptoms continue despite an appropriate initial treatment course.+
    1. 1Verify adherence, actual PPI timing, H pylori test validity, NSAID exposure and whether the dominant symptom remains dyspepsia.
    2. 2AlternativeReassess warning features and alternative cardiac, biliary, pancreatic, medication and gastroparesis clues, repeating examination and selected bloods where the phenotype changed.
    3. 3Arrange endoscopy or targeted imaging when the unresolved question justifies it, and use gastroenterology review for refractory or diagnostically discordant symptoms.
    4. 4If structural assessment is negative and the phenotype fits functional dyspepsia, explain the diagnosis and offer layered dietetic, acid-suppressing, neuromodulatory and psychological options.
    04Long-term reviewMinimise treatment burden safelySymptoms are controlled on ongoing acid suppression or after eradication.+
    1. 1Confirm the continuing indication, using the lowest effective dose, intermittent strategy or cessation where clinically appropriate.
    2. 2Review NSAID and gastroprotection need, adherence, adverse effects and any recurrence pattern at medication reviews.
    3. 3Investigate new dysphagia, bleeding, anaemia, vomiting or weight loss as a new presentation rather than automatically increasing PPI treatment.
    Key medicines and prescribing safety2 treatments · regimens, roles and cautions+
    Reduces acid-related symptoms and promotes healing in relevant ulcer or reflux disease while the diagnostic pathway is completed.

    Proton-pump inhibitor

    Use a full-dose four-week course for uninvestigated dyspepsia under NICE, then step down to the lowest effective or intermittent approach after response review.

    Arrange a two-week washout before breath or stool H pylori testing. Review interactions, long-term indication and adverse-effect burden, and do not let response defer investigation of alarm features.

    Eradicates a major cause of peptic ulcer disease and may improve H pylori-associated dyspepsia.

    Helicobacter pylori eradication therapy

    Give the current locally recommended one-week combination regimen selected for penicillin allergy, previous antibiotic exposure and regional resistance, then support full adherence.

    Check allergies, interactions and antimicrobial history. Failed therapy should not be repeated blindly; follow local rescue and confirmation guidance, and investigate alarm symptoms independently of infection status.